Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy

In solid tumors without routine HER2 expression assessment and no approved anti-HER2 treatments, comprehensive genomic profiling (CGP) is crucial, as it not only helps determine eligibility for existing targeted therapies but also identifies genomic ERBB2 alterations that could respond to emerging anti-HER2 antibody-drug conjugates in clinical development, expanding potential treatment options for patients with limited choices.